MERCK & CO INC

Merck’s new drug tulisokibart shows 72% of hidradenitis suppurativa patients improve >50% in a mid‑stage trial, boosting its immunology platform and offering a key revenue hedge before Keytruda’s patent expiry.

Merck’s global license for SPR2015, a pre‑clinical oral KRAS G12D inhibitor, could add a $2.13 bn‑value precision therapy to its oncology line‑up.

Merck’s latest regulatory wins—WINREVAIR PAH update, a streamlined Keytruda biosimilar path, and Japan’s SC Keytruda QLEX—boost market access, cut launch costs, and secure new revenue streams across oncology, pulmonary and cardiovascular sectors.

Merck & Co. steadies the Dow with modest gains, showing resilience amid market shifts and macro‑economic pressure on pharma stocks.

Merck’s mRNA‑based melanoma vaccine, paired with pembrolizumab, boosts 24‑month overall survival by 33% and doubles response rates, promising a breakthrough in personalized cancer therapy.

Merck’s phase‑III win shows a personalized mRNA melanoma vaccine boosts Keytruda’s survival rates, opening a new era for tailored cancer therapies.

Merck’s Phase‑3 success for a personalized mRNA melanoma vaccine fuels an 8% share jump and signals a new, fast‑tracked oncology therapy.

Merck’s Phase III success with sonesitatug vedotin shows first‑in‑class CLDN18.2‑targeted therapy for gastric cancer, offering new survival benefits and a clear value‑based pricing strategy.

Merck’s new once‑daily oral PCSK9 inhibitor boosts patient adherence while meeting cost‑effectiveness thresholds, positioning the company for $600 M+ revenue in a $170 B cardiovascular market.

Merck & Immutep’s eftilagimod alfa boosts KEYTRUDA’s reach in low‑PD‑L1 NSCLC, promising up to $3‑5 billion in future sales and a new competitive niche.